| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
4 homozygotes
From the Department of Neurology (Dr. Caselli), the Division of Biostatistics (A. Weaver), and the Division of Psychology (Dr. Osborne), Mayo Clinic Scottsdale, AZ; the Department of Neurology (Drs. Graff–Radford and Lucas), Mayo Clinic Jacksonville, FL; the Department of Psychiatry (Dr. Reiman), University of Arizona and Samaritan Positron Emission Tomography Center, Phoenix, AZ; the Arizona Research Laboratories Division of Neural Systems, Memory, and Aging (Dr. Ueker), University of Arizona, Tucson, AZ; and the Department of Laboratory Medicine (Dr. Thibodeau), Mayo Clinic, Rochester, MN.
Address correspondence and reprint requests to Dr. Richard J. Caselli, Department of Neurology, Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85259.
OBJECTIVE: To determine, in a cross-sectional evaluation of nondemented individuals, if age-related memory decline is influenced by apolipoprotein E (apoE) genotype.
BACKGROUND: The apoE-4 allele is an important risk factor for AD. PET in cognitively normal apoE-4 carriers (mean age, 56 years) shows reduced cerebral metabolism suggestive of very early AD that precedes clinically evident memory loss or MRI-based hippocampal atrophy.
METHODS: Tests of immediate and delayed recall (primary outcome measures) and other neuropsychological measures (secondary outcome measures) were given to three genetically defined groups of cognitively normal individuals (age, 49 to 69 years) including apoE-4 homozygotes (n = 25), apoE-4 heterozygotes (n = 25, all 
3/4), and apoE-4 noncarriers (n = 50). Groups were matched for age, gender, and educational background. Cross-sectional comparisons between the genetic subgroups of the relationship between age and test score were performed for each neuropsychological measure.
RESULTS: There were no intergroup differences in mean scores on any neuropsychological measure, but tests sensitive to immediate and delayed recall showed a significant negative correlation with age in the apoE-4 homozygote group relative to the noncarrier group.
CONCLUSION: Consistent with previous neuropsychological studies of early AD, this cross-sectional study suggests that age-related memory decline occurs earlier in cognitively healthy apoE-4 homozygotes than in apoE-4 heterozygotes and noncarriers, and precedes clinically detectable AD.
This article has been cited by other articles:
|
|
 |
|
  S. C. Johnson, T. W. Schmitz, M. A. Trivedi, M. L. Ries, B. M. Torgerson, C. M. Carlsson, S. Asthana, B. P. Hermann, and M. A. Sager The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation. J. Neurosci., May 31, 2006; 26(22): 6069 - 6076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. W. Bokde, P. Lopez-Bayo, T. Meindl, S. Pechler, C. Born, F. Faltraco, S. J. Teipel, H.-J. Moller, and H. Hampel Functional connectivity of the fusiform gyrus during a face-matching task in subjects with mild cognitive impairment Brain, May 1, 2006; 129(5): 1113 - 1124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Devanand, G. H. Pelton, D. Zamora, X. Liu, M. H. Tabert, M. Goodkind, N. Scarmeas, I. Braun, Y. Stern, and R. Mayeux Predictive Utility of Apolipoprotein E Genotype for Alzheimer Disease in Outpatients With Mild Cognitive Impairment Arch Neurol, June 1, 2005; 62(6): 975 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Mosconi, K Herholz, I Prohovnik, B Nacmias, M T R De Cristofaro, M Fayyaz, L Bracco, S Sorbi, and A Pupi Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve J. Neurol. Neurosurg. Psychiatry, January 1, 2005; 76(1): 15 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Caselli, E. M. Reiman, J. G. Hentz, D. Osborne, and G. E. Alexander A Distinctive Interaction Between Chronic Anxiety and Problem Solving in Asymptomatic APOE e4 Homozygotes J Neuropsychiatry Clin Neurosci, August 1, 2004; 16(3): 320 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Caselli, E. M. Reiman, D. Osborne, J. G. Hentz, L. C. Baxter, J. L. Hernandez, and G. G. Alexander Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele Neurology, June 8, 2004; 62(11): 1990 - 1995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Mosconi, B Nacmias, S Sorbi, M T R De Cristofaro, M Fayazz, A Tedde, L Bracco, K Herholz, and A Pupi Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer's disease J. Neurol. Neurosurg. Psychiatry, March 1, 2004; 75(3): 370 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Buttini, G.-Q. Yu, K. Shockley, Y. Huang, B. Jones, E. Masliah, M. Mallory, T. Yeo, F. M. Longo, and L. Mucke Modulation of Alzheimer-Like Synaptic and Cholinergic Deficits in Transgenic Mice by Human Apolipoprotein E Depends on Isoform , Aging, and Overexpression of Amyloid beta Peptides But Not on Plaque Formation J. Neurosci., December 15, 2002; 22(24): 10539 - 10548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A G Yip, C Brayne, D Easton, and D C Rubinsztein Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population J. Med. Genet., September 1, 2002; 39(9): 639 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Friedland, T. Fritsch, K. A. Smyth, E. Koss, A. J. Lerner, C. H. Chen, G. J. Petot, and S. M. Debanne Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members PNAS, March 1, 2001; (2001) 61002998. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. D. Bigler, C. M. Lowry, C. V. Anderson, S. C. Johnson, J. Terry, and M. Steed Dementia, Quantitative Neuroimaging, and Apolipoprotein E Genotype AJNR Am. J. Neuroradiol., November 1, 2000; 21(10): 1857 - 1868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Greenwood, T. Sunderland, J. L. Friz, and R. Parasuraman Genetics and visual attention: Selective deficits in healthy adult carriers of the varepsilon 4 allele of the apolipoprotein E gene PNAS, October 10, 2000; 97(21): 11661 - 11666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Small, A. B. Graves, C. L. McEvoy, F. C. Crawford, M. Mullan, and J. A. Mortimer Is APOE-{epsilon}4 a risk factor for cognitive impairment in normal aging? Neurology, June 13, 2000; 54(11): 2082 - 2088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Dik, C. Jonker, L. M. Bouter, M. I. Geerlings, G. J. van Kamp, and D. J. H. Deeg APOE-{epsilon}4 is associated with memory decline in cognitively impaired elderly Neurology, April 11, 2000; 54(7): 1492 - 1497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Friedland, T. Fritsch, K. A. Smyth, E. Koss, A. J. Lerner, C. H. Chen, G. J. Petot, and S. M. Debanne Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members PNAS, March 13, 2001; 98(6): 3440 - 3445. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
